A European Reference Network for Rare Hematological Diseases

You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.

Burnouts: when caregivers become patients

Author: Côme Bommier (Young EHA Ambassador)
Affiliations: Hôpital St-Louis (Paris, France) & Mayo Clinic (Rochester MN, USA)

A survey will be released in September to further map burnout
among hematology professionals in Europe.

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Recommendations for COVID-19

Is CBTH for me?

CBTH provides the development of computational biology skills for scholars who want to build successful careers in hematology research.

For mentors of applicants

As part of your support for the candidate applying for CBTH, the following is required from you:

Supervision and mentorship to be provided to the applicant during the CBTH award year.

Is TRTH for me?

Please see the eligibility criteria in the dropdown menu below.

Is CRTH for me?

Eligibility
Applicant must be a trainee or junior faculty and hold an MD or MD/PhD 
Applicant must be actively employed in a hematology or hematology-related research environment 
The applicant must be an EHA member or EHA Guest at the time of application submission…

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).